Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02831257 · ClinicalTrials.gov registry record · Phase 2
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
A Phase 2 study of Meningioma and Neurofibromatosis 2, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT02831257 is a Phase 2 study of Meningioma and Neurofibromatosis 2 that has completed, run by Massachusetts General Hospital. The registered enrollment target is 18 participants, below the 99-participant average among 21 other Meningioma trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02831257, a Phase 2 study of Meningioma and Neurofibromatosis 2, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.
Conditions Studied
Interventions
- DRUG AZD2014
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02831257
The ClinicalTrials.gov registry entry for NCT02831257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 21 other Meningioma trials with a reported enrollment target (82% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Meningioma appearing as the primary indexed condition, and to 1 intervention - of which AZD2014 is the first listed.
NCT02831257 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02831257 about?
NCT02831257 is a clinical study titled "AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas". The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.
What is the current status of trial NCT02831257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-08-31. Estimated completion is 2020-10-01.
What conditions does trial NCT02831257 study?
This clinical trial studies the following conditions: Meningioma, Neurofibromatosis 2.
What interventions are being tested in trial NCT02831257?
The interventions under investigation include: AZD2014 (DRUG).
Who is sponsoring clinical trial NCT02831257?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02831257 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
Monthly SOM230C for Recurrent or Progressive Meningioma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.